Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel

NCT02175446 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT02175446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02175446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel
Lead sponsor
Consorzio Oncotech
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2014
Completion date
December 31, 2017
Enrollment
61 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

human epidermal growth factor 2 negative carcinoma of breast, metastatic breast cancer